Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 295

1.

CASTLE tumor of the parotid: First documented case, literature review, and genetic analysis of the cancer.

Wong EHC, Tetter N, Tzankov A, Muller L.

Head Neck. 2017 Nov 9. doi: 10.1002/hed.24985. [Epub ahead of print]

PMID:
29120527
2.

Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study.

Magaton IM, Tzankov A, Krasniqi F, Rottenburger C, Zanetti-Daellenbach R, Grendelmeier P, Heinzelmann-Schwarz V, Mayr M, Schwab FD.

Case Rep Oncol. 2017 Oct 5;10(3):876-884. doi: 10.1159/000480696. eCollection 2017 Sep-Dec.

3.

Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.

Juskevicius D, Müller A, Hashwah H, Lundberg P, Tzankov A, Menter T.

Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1387903. [Epub ahead of print]

PMID:
29043881
4.

PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma.

Haefliger S, Bihl M, Krasniqi F, Tzankov A.

Ann Hematol. 2017 Oct 3. doi: 10.1007/s00277-017-3145-0. [Epub ahead of print] No abstract available.

PMID:
28975389
5.

Lymphomdiagnostik durch den Pathologen – von der Morphologie über den Immunphänotyp bis zur Genanalyse.

Menter T, Tzankov A, Dirnhofer S.

Ther Umsch. 2017 Sep;74(4):197-203. doi: 10.1024/0040-5930/a000904. German. No abstract available.

PMID:
28950777
6.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

PMID:
28949959
7.

Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.

Weixler B, Renetseder F, Facile I, Tosti N, Cremonesi E, Tampakis A, Delko T, Eppenberger-Castori S, Tzankov A, Iezzi G, Kettelhack C, Soysal SD, von Holzen U, Spagnoli GC, Terracciano L, Tornillo L, Droeser RA, Däster S.

Cell Oncol (Dordr). 2017 Sep 21. doi: 10.1007/s13402-017-0348-2. [Epub ahead of print]

PMID:
28936810
8.

Response to the letter to the editor of Lambros et al.

Sterlacci W, Tzankov A, Savic S.

Virchows Arch. 2017 Nov;471(5):687-688. doi: 10.1007/s00428-017-2230-z. Epub 2017 Sep 7. No abstract available.

PMID:
28879608
9.

Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments.

Muraro MG, Muenst S, Mele V, Quagliata L, Iezzi G, Tzankov A, Weber WP, Spagnoli GC, Soysal SD.

Oncoimmunology. 2017 May 30;6(7):e1331798. doi: 10.1080/2162402X.2017.1331798. eCollection 2017.

PMID:
28811974
10.

Broken heart by T-prolymphocytic leukemia.

Arranto C, Tzankov A.

Blood. 2017 Aug 3;130(5):691. doi: 10.1182/blood-2017-05-784363. No abstract available.

PMID:
28775161
11.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.222. [Epub ahead of print]

PMID:
28745330
12.

Beneficial role of increased FOXP3+ regulatory T-cells in acute myeloid leukaemia therapy response.

Menter T, Kuzmanic B, Bucher C, Medinger M, Halter J, Dirnhofer S, Tzankov A.

Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14819. [Epub ahead of print] No abstract available.

PMID:
28653378
13.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

PMID:
28627414
14.

A pattern-based approach to reactive lymphadenopathies.

Tzankov A, Dirnhofer S.

Semin Diagn Pathol. 2017 May 25. pii: S0740-2570(17)30060-6. doi: 10.1053/j.semdp.2017.05.002. [Epub ahead of print] Review.

PMID:
28619469
15.

Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.

Matter MS, Bihl M, Juskevicius D, Tzankov A.

Virchows Arch. 2017 Oct;471(4):545-547. doi: 10.1007/s00428-017-2173-4. Epub 2017 Jun 9. No abstract available.

PMID:
28597077
16.

Genetic background and evolution of relapses in aggressive B-cell lymphomas.

Juskevicius D, Dirnhofer S, Tzankov A.

Haematologica. 2017 Jul;102(7):1139-1149. doi: 10.3324/haematol.2016.151647. Epub 2017 May 29. Review.

17.

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A.

Virchows Arch. 2017 Jul;471(1):49-55. doi: 10.1007/s00428-017-2131-1. Epub 2017 May 20.

PMID:
28528511
18.

Mutational landscape of B-cell post-transplant lymphoproliferative disorders.

Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN.

Br J Haematol. 2017 Jul;178(1):48-56. doi: 10.1111/bjh.14633. Epub 2017 Apr 17.

PMID:
28419429
19.

Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas.

Menter T, Trivedi P, Ahmad R, Flora R, Dirnhofer S, Tzankov A, Naresh KN.

Am J Clin Pathol. 2017 Mar 1;147(3):292-300. doi: 10.1093/ajcp/aqw208.

PMID:
28395058
20.

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.

Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A.

J Hematol Oncol. 2017 Mar 17;10(1):70. doi: 10.1186/s13045-017-0438-7.

Supplemental Content

Loading ...
Support Center